
Daiichi Sankyo hires two new executives
pharmafile | October 7, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |Â Â Daiichi SankyoÂ
Daiichi Sankyo has appointed Glenn Gormley to be its corporate president and chairman, and Greg Barrett as a new acting head.
Gormley (pictured) will be continuing in his existing roles as president of pharma development, global head of R&D and senior executive officer at the New Jersey, US-based company.
In addition, Greg Barrett has been appointed as the new acting head of the commercial division of the firm in the US.
Daiichi Sankyo’s former president and chief executive – and head of its commercial division – John Gargiulo, left the company on 3 October.
Barrett will hold the new title of acting president, administrative & commercial operations. In this role Barrett will be responsible for leading the Daiichi Sankyo US commercial division including marketing, sales and supply chain operations.
Barrett most recently held the position of vice president, marketing and managed markets at Daiichi Sankyo, and has been with the company since the late 1990s.
Related Content

AAX Biotech and Daiichi Sankyo partner to evaluate antibody therapeutics
AAX Biotech, a Swedish biotechnology company specialising in next-generation antibody therapeutics, has launched a strategic …

Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …

AstraZeneca shares results from phase 3 TROPION-Lung01 trial
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s …






